IN8BIO, Inc. (INAB): Total Liabilities
$4.72M
As of 2025-12-31
$3.38M
As of 2026-06-30
-22.9%
3-year compound annual growth
+12.8%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $4.72M | -26.9% | 2026-03-12, Balance as of period end |
| 2024-12-31 | $6.47M | -26.3% | 2026-03-12, Balance as of period end |
| 2023-12-31 | $8.77M | -14.9% | 2025-03-13, Balance as of period end |
| 2022-12-31 | $10.31M | +155.1% | 2024-03-14, Balance as of period end |
| 2021-12-31 | $4.04M | +56.0% | 2023-03-30, Balance as of period end |
| 2020-12-31 | $2.59M | n/a | 2022-03-17, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| IN8BIO, Inc. (INAB) | 2025-12-31 | $4.72M | -26.9% |
| Inmune Bio, Inc. (INMB) | 2025-12-31 | $8.83M | +18.2% |
| Jasper Therapeutics, Inc. (JSPR) | 2025-12-31 | $31.63M | +73.5% |
| CEL SCI Corp (CVM) | 2025-09-30 | $12.20M | -13.6% |
| Windtree Therapeutics Inc (WINT) | 2024-12-31 | $14.70M | -49.3% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $22.92M | -19.8% |
| Ocugen, Inc. (OCGN) | 2025-12-31 | $55.68M | +5.4% |
| Black Hawk Acquisition Corp (BKHA) | 2025-11-30 | $3.90M | +56.8% |
| PharmaCyte Biotech, Inc. (PMCB) | 2026-04-30 | $11.77M | +259.2% |
Compare INAB, INMB, JSPR, CVM side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗